Tools for Practice Outils pour la pratique

#256 Hydroxychloroquine with or without azithromycin for COVID-19

Is hydroxychloroquine (with or without azithromycin) effective in treating COVID-19?

One nonrandomized study found that more hydroxychloroquine/azithromycin patients tested negative for virus at days 3 and 6 but clinical outcomes were not reported. One unblinded randomized trial showed no effect from hydroxychloroquine on viral or clinical outcomes. Without further evidence, hydroxychloroquine is not appropriate for patients with COVID-19 in primary care.  

CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session

One non-blinded randomized study in China (30 in-patientsmean age 48).1 
  • Hydroxychloroquine 400 mg daily for 5 days was given to one group and both groups received conventional treatments. 
    • Number with negative PCR nasopharyngeal swab: 
Day 7  Adverse effects (examples diarrhea and elevated aspartate aminotransferase) 
Control  14/15 (93%)  3/15 
Hydroxychloroquine  13/15 (87%)  4/15 
    • Median time to temperature normalization was 1 day in each group. 
    • All patients survived. 
    • Limitations: not blinded. Much of the text was in Chinese.  
One non-randomized study in France (42 in-patients, mean age 45) of hydroxychloroquine 200mg three times daily for 10 days.2 Antibiotics could be added to prevent bacterial superinfection based on clinical judgement (azithromycin 500mg for 1 day then 250mg daily for 4 days). 
  • Number with negative PCR nasopharyngeal swab:   
  Day 3  Day 6 
Control  1/16 (6%)  2/16 (13%) 
Hydroxychloroquine  5/14 (36%)  8/14 (57%) 
Hydroxychloroquine + Azithromycin  5/6 (83%)  6/6 (100%) 
Limitations: not randomized, no clinical outcomes or adverse effects reported, 6 hydroxychloroquine patients lost to follow-up and not analyzed (including 1 death and 3 transferred to critical care).  Context: 
  • There are no studies evaluating the use of hydroxychloroquine to prevent COVID-19 infection. 
  • At least 23 other clinical trials currently in progress.3 
  • Both azithromycin and hydroxychloroquine are associated with an increased risk of sudden cardiac death from QT prolongation.4 
  • Applying early data, when we really need treatments and hope, is challenging. However, interventions that have not been verified to provide clinical/symptomatic benefits for hospitalized patients with COVID-19 are unlikely to benefit patients in primary care. 

Latest Tools for Practice
Derniers outils pour la pratique

#363 Making a difference in indifference? Medications for apathy in dementia

In patients with dementia, how safe and effective are stimulants, antidepressants, and antipsychotics for treating apathy?
Read Lire 0.25 credits available Crédits disponibles

#362 Facing the Evidence in Acne, Part I: Oral contraceptives and spironolactone in females

How effective are combined oral contraceptives (COC) and spironolactone for treating acne of at least mild-moderate severity in females?
Read Lire 0.25 credits available Crédits disponibles

#361 Preventing RSV Infections in Infants

How safe and effective are monoclonal antibodies to prevent respiratory syncytial virus (RSV) infections in infants?
Read Lire 0.25 credits available Crédits disponibles

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session

  • James McCormack BSc(Pharm) PharmD
  • Adrienne J Lindblad BSP ACPR PharmD

1. Chen J, Liu D, Liu L, et al. J Zhejiang Univ. March 2020. Available from:  - English abstract - Chinese content translated by google translate. Accessed 25 Mar 2020. 

2. Gautret P, Lagier JC, Parola P, et al. Int J Antimicrob Agents. 2020 Mar 17 (in press). DOI: 10.1016/j.ijantimicag.2020.105949.

3. Cortegiani A, Ingoglia G, Ippolito M, et al. J Crit Care. 2020 (in press). DOI: 10.1016/j.jcrc.2020.03.005

4. Woosley RL, Heise CW, Gallo T, et al., QTdrugs List. Oro Valley, AZ: AZCERT, Inc. Accessed 26 March 2020.

Authors do not have any conflicts of interest to declare.

Les auteurs n’ont aucun conflit d’intérêts à déclarer.